BriaCell Therapeutics (BCTX) said Friday it priced a public offering of 3.07 million units at $4.50 each, to raise gross proceeds of about $13.8 million.
Each unit includes one common share and one warrant to buy another share at $5.25, exercisable immediately and valid for five years, the company said.
The warrants will begin trading on Nasdaq under the ticker "BCTXZ" on Friday, the company said, adding the offering is expected to close on Monday, with proceeds going toward working capital and general corporate purposes.
BriaCell shares were down more than 21% in premarket trading.